Accueil   Diary - News   All news Mediolanum Farmaceutici acquires the French company ElsaLys Biotech to develop next generation immuno-oncology therapies

Mediolanum Farmaceutici acquires the French company ElsaLys Biotech to develop next generation immuno-oncology therapies

 

Thanks to acquisition, the Italian pharmaceutical Group strengthens its commitment to Research & Development in Oncology, and consolidate its international expansion process.

 


Milan, May 7th 2020 – Mediolanum Farmaceutici Spa, a leading Italian pharmaceutical Group operating on the international scene, focused on research, development, production and distribution of innovative and original medicines to improve patients’ health and quality of life, announced that it has acquired the French company ElsaLys Biotech.


ElsaLys Biotech is a clinical stage immuno-oncology company that designs and develops a new generation of therapeutic antibodies that target tumours and their immune and vascular microenvironment.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree